Molecular diagnosis of prostate cancer

被引：3
作者：
Canto E.I. [1 ]
Shariat S.F. [1 ]
Slawin K.M. [1 ]
机构：
[1] Scott Department of Urology, Baylor College of Medicine, The Baylor Prostate Center, 6560 Fannin Street, Suite 2100, Houston, 77030, TX
来源：
Current Urology Reports | 2004年 / 5卷 / 3期
关键词：
Prostate Cancer; Prostate Cancer Detection; Prostate Cancer Screening; Prostate Volume; Seminal Plasma;
D O I：
10.1007/s11934-004-0038-2
中图分类号：
学科分类号：
摘要：
The diagnosis, staging, and management of prostate cancer as we know it today is greatly dependent on our ability to measure serum prostate-specific antigen (PSA) concentration. Nevertheless, because serum PSA concentration, particularly when less than 10 ng/mL, reflects the presence of benign prostatic hyperplasia more often than cancer, there is a clear need for more specific prostate cancer markers. The most promising new markers for prostate cancer are the various molecular forms of free PSA. Mass spectrometry also is emerging as a potential tool in prostate cancer screening. Because it is unlikely that any one marker will have 100% sensitivity and specificity, as new serum markers are tested, nomograms that incorporate multiple independently predictive parameters for the detection of prostate cancer will become indispensable in our efforts to improve prostate cancer screening. © 2004, Current Science Inc.
引用
收藏
页码：203 / 211
页数：8
相关论文
共 59 条
  • [41] Niemela P., Lovgren J., Karp M., Et al., Sensitive and specific enzymatic assay for the determination of precursor forms of prostate-specific antigen after an activation step, Clin Chem, 48, pp. 1257-1264, (2002)
  • [42] Steuber T., Nurmikko P., Haese A., Et al., Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen, J Urol, 168, pp. 1917-1922, (2002)
  • [43] Chen Z., Chen H., Stamey T.A., Prostate-specific antigen in benign prostatic hyperplasia: purification and characterization, J Urol, 157, pp. 2166-2170, (1997)
  • [44] Zhang W.M., Leinonen J., Kalkkinen N., Et al., Purification and characterization of different molecular forms of prostatespecific antigen in human seminal fluid, Clin Chem, 41, pp. 1567-1573, (1995)
  • [45] Wang T.J., Slawin K.M., Rittenhouse H.G., Et al., Benign prostatic hyperplasia-associated prostate-specific antigen (BPSA) shows unique immunoreactivity with anti-PSA monoclonal antibodies, Eur J Biochem, 267, pp. 4040-4045, (2000)
  • [46] Canto E.I., Singh H., Shariat S.F., Serum BPSA outperforms both total PSA and free PSA as a predictor of prostate enlargement in men without prostate cancer. Urology, (2004)
  • [47] Linton H.J., Marks L.S., Millar L.S., Et al., Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease, Clin Chem, 49, pp. 253-259, (2003)
  • [48] Morote J., Encabo G., Lopez M., de Torres I.M., Prediction of prostate volume based on total and free serum prostate-specific antigen: Is it reliable?, Eur Urol, 38, pp. 91-95, (2000)
  • [49] Canto E.I., Singh H., Shariat S.F., Et al., Comparison of %fPSA, %BPSA, [-2]pPSA/fPSA, and [-2]pPSA/BPSA for prostate cancer detection in men with total serum PSA concentrations between 4 and 10 ng/nL. Presented at the 99th Annual Meeting of the American Urological Association, San Francisco: May, pp. 8-13, (2004)
  • [50] Rittenhouse H.G., Finlay J.A., Mikolajczyk S.D., Partin A.W., Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate, Crit Rev Clin Lab Sci, 35, pp. 275-368, (1998)
123456